(Q50895752)

24 March 2018

title

Angiotensin-converting enzyme inhibitors in heart failure: physicians' prescribing behavior. (English)

1 reference

24 March 2018

0 references

2

1 reference

24 March 2018

author name string

Ferreira A

1

1 reference

24 March 2018

Cortez M

3

1 reference

24 March 2018

Araújo JP

4

1 reference

24 March 2018

Cerqueira-Gomes M

5

1 reference

24 March 2018

publication date

1 December 1997

1 reference

24 March 2018

Journal of Cardiac Failure

published in

1 reference

24 March 2018

volume

3

1 reference

24 March 2018

issue

4

1 reference

24 March 2018

page(s)

295-302

1 reference

24 March 2018

A placebo-controlled trial of captopril in refractory chronic congestive heart failure. Captopril Multicenter Research Group

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Comparison of captopril and enalapril in patients with severe chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Tolerability of enalapril in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Perspective of the pharmaceutical industry on the development of new drugs for heart failure.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure in two community hospitals

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

An analysis of physicians' reasons for prescribing long-term digitalis therapy in outpatients

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

The need for a sodium retention score in clinical trials of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

The Effect of the Angiotensin-Converting–Enzyme Inhibitor Zofenopril on Mortality and Morbidity after Anterior Myocardial Infarction

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Efficacy of captopril in postponing nephropathy in normotensive insulin dependent diabetic patients with microalbuminuria.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Effect of captopril on progression to clinical proteinuria in patients with insulin-dependent diabetes mellitus and microalbuminuria. European Microalbuminuria Captopril Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Renal hemodynamic consequences of angiotensin-converting enzyme inhibition in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Aldosterone and antialdosterone therapy in congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Magnesium deficiency and sudden death

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1071-9164%2897%2990029-4

7 January 2021

10.1016/S1071-9164(97)90029-4

Identifiers

DOI

1 reference

24 March 2018

1 reference

24 March 2018